RUS 350

Drug Profile

RUS 350

Alternative Names: RUS350

Latest Information Update: 01 Oct 2010

Price : $50

At a glance

  • Originator Cambridge Laboratories
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Huntington's disease

Most Recent Events

  • 28 Sep 2010 Biovail Corporation merged with Valeant Pharmaceuticals International forming Valeant Pharmaceuticals International
  • 22 May 2009 Phase-I clinical trials in Huntington's disease in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top